3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension

Study Overview
=================
Brief Summary
-----------------
Pulmonary hypertension is a rare and severe disease, affecting a young population. Survival is very poor and has been closely related to right ventricular dysfunction. Current prognostic equations rely mostly on right heart catheterization data. The identification of simple echocardiographic prognostic factor is urgently needed. It could help identifying with a non invasive method, high risk patients who could benefit from an intensive specific therapy. 3D right ventricular imaging is a new echocardiographic tool which provides RV volumic analysis, RV ejection fraction, overcoming the classical limits of 2D ultrasound. The aim of this study is to validate a new software for 3D analysis of the right ventricle and assess its prognostic role in pulmonary hypertension. To do so, the investigators will realize a prospective monocentric longitudinal cohort study, including 100 pulmonary hypertension patients. Echocardiographic data will be collected at baseline and after 6 months.

Official Title
-----------------
3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension

Conditions
-----------------
Pulmonary Arterial Hypertension

Intervention / Treatment
-----------------
* Device: 3D right ventricular imaging echocardiographic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients > 18 years old Pulmonary hypertension diagnosed by right heart catheterization Informed consent obtained Affiliation to the French national health insurance Exclusion Criteria: Associated significant left heart disease Sub-optimal acoustic windows Patient unable to attend follow-up visits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months | Device: 3D right ventricular imaging echocardiographic<br>* Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.<br>|
| Control<br>Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline | Device: 3D right ventricular imaging echocardiographic<br>* Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of death from any cause | Description of the number of death during the study | Baseline to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Hospitalisation | Description of the number of hospitalisation for worsening of pulmonary arterial hypertension | Baseline to 24 months | 
| 3D right ventricular imaging echocardiographic | Analyse the data of 3D right ventricular (RV), ejection fraction, RV telediastolic and telesystolic volume, 3D RV area strain (%) | Baseline and 6 months |